This discovery broadens the understanding of the STING signaling pathway’s functions beyond enhancing antitumor immunity [60, 61], establishes a connection between the STING signaling pathway and sorafenib resistance in HCC cells, and provides a theoretical basis for the combined use of sorafenib and STING inhibitors to reverse liver cancer drug resistance. The gene discussed is STING1; the disease is hepatocellular carcinoma.